The insulin-like growth factor system and its receptors: A potential novel anticancer target.
The current generation of novel anticancer therapies that are in preclinical and clinical development are based on exploiting our increasing understanding of the molecular and cellular basis of cancer development and progression. Accelerated rates of cell division and proliferation have been postulated to predispose to the development of malignant disease. The insulin-like growth factor (IGF) signaling system has an important physiological role in regulating cellular proliferation and apoptosis. This function has led to considerable interest in its relevance to neoplasia over the last decade. In this review, we give an overview of the IGF system physiology, discuss the epidemiological significance of IGF signaling and neoplasia, and review the preclinical and clinical studies in targeting IGF receptors as cancer therapies.
Lindsay
Colin R
CR
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;
Evans
Tr Jeffry
TJ
J Natl Cancer Inst. 1999 Dec 1;91(23):2052
10580039
Cancer Res. 1998 Aug 1;58(15):3353-61
9699666
Nat Rev Cancer. 2004 Jul;4(7):505-18
15229476
Carcinogenesis. 2006 Dec;27(12):2464-8
16777984
Br J Cancer. 2006 Feb 27;94(4):465-8
16450000
Cancer Res. 2005 Dec 1;65(23):11118-28
16322262
J Biol Chem. 1997 Dec 5;272(49):31163-71
9388270
Mol Cell Endocrinol. 1997 May 16;129(2):121-6
9202395
Science. 1997 May 23;276(5316):1268-72
9157888
Lancet. 1998 Aug 8;352(9126):489
9708783
Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s
17875788
Mol Cell Biol. 1994 Jun;14(6):3604-12
8196606
Int J Cancer. 1991 Aug 19;49(1):114-7
1874564
Clin Cancer Res. 2005 Mar 1;11(5):2063-73
15756033
Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):84-9
12582016
Endocr Rev. 2000 Jun;21(3):215-44
10857553
Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E967-76
10826997
Clin Cancer Res. 2007 May 1;13(9):2795-803
17473213
Gut. 2002 May;50(5):642-6
11950809
Eur J Cancer. 1993;29A(4):492-7
8435198
Cancer Immunol Immunother. 2007 Mar;56(3):343-57
16832681
Cancer Lett. 2003 Jun 10;195(2):127-37
12767520
Endocrinol Metab Clin North Am. 1996 Sep;25(3):591-614
8879988
Life Sci. 2007 May 16;80(23):2161-2169
17499312
Clin Cancer Res. 1995 Dec;1(12):1471-8
9815946
Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):935-8
12223442
Br J Cancer. 2003 Oct 6;89(7):1237-42
14520453
J Biol Chem. 1994 May 13;269(19):13779-84
7514593
J Clin Oncol. 2004 Aug 1;22(15):3104-12
15284261
Clin Cancer Res. 2007 Oct 1;13(19):5834-40
17908976
Cancer Res. 1999 Aug 1;59(15):3588-91
10446966
Cancer Res. 2006 Jan 1;66(1):362-71
16397250
N Engl J Med. 1987 Jul 16;317(3):137-40
3299085
Endocrinology. 1997 Mar;138(3):1355-8
9048647
Epidemiol Rev. 2001;23(1):59-66
11588855
Cancer Cell. 2004 Mar;5(3):231-9
15050915
J Cancer Res Clin Oncol. 1995;121(11):674-82
7593132
J Natl Cancer Inst. 1996 Mar 20;88(6):340-8
8609642
Science. 1988 Mar 4;239(4844):1134-7
2964083
Cancer Res. 2003 Aug 15;63(16):5073-83
12941837
J Biol Chem. 2003 May 2;278(18):15991-7
12604614
Am J Clin Nutr. 2001 Oct;74(4):549-54
11566656
JAMA. 2005 May 25;293(20):2479-86
15914748
Br J Cancer. 2002 Oct 7;87(8):876-82
12373602
Cancer Gene Ther. 2000 Mar;7(3):384-95
10766344
Int J Cancer. 2002 Sep 1;101(1):11-6
12209582
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1250-5
12538852
Endocr Rev. 2002 Dec;23(6):824-54
12466191
J Am Geriatr Soc. 1994 Jan;42(1):71-6
8277119
Int J Cancer. 1996 Mar 15;65(6):812-20
8631597
Int J Cancer. 2008 Jan 15;122(2):267-73
17918158
Cell Growth Differ. 2002 Feb;13(2):87-93
11864912
Cell. 1993 Oct 8;75(1):59-72
8402901
J Clin Oncol. 2004 Mar 1;22(5):785-94
14990633
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3455-60
10737798
Cancer Cell. 2004 Mar;5(3):221-30
15050914
Neoplasia. 2002 May-Jun;4(3):204-17
11988840
Proc Soc Exp Biol Med. 1998 Feb;217(2):143-52
9452137
Diabetologia. 1991 Mar;34(3):144-9
1884885
Epidemiology. 1995 Jul;6(4):423-4
7548353
J Clin Endocrinol Metab. 1996 Oct;81(10):3774-82
8855837
Mol Cancer Ther. 2007 Aug;6(8):2158-67
17671083
Oncogene. 2001 Nov 8;20(51):7542-50
11709726
Cancer Res. 2003 Feb 1;63(3):627-35
12566306
Mol Carcinog. 2003 Mar;36(3):142-6
12619036
Cell. 1991 Feb 22;64(4):849-59
1997210
Cancer Res. 1997 Nov 1;57(21):4667-72
9354418
BMJ. 2007 Dec 1;335(7630):1134
17986716
Clin Cancer Res. 2002 Oct;8(10):3259-69
12374697
Endocr Rev. 1995 Feb;16(1):3-34
7758431
Diabetes. 1996 Jan;45(1):91-100
8522066
Int J Cancer. 1994 May 15;57(4):491-7
7514152
Cancer Res. 2003 Aug 1;63(15):4384-8
12907608
Clin Cancer Res. 2007 Jun 15;13(12):3611-6
17575225
Clin Endocrinol (Oxf). 1994 Sep;41(3):351-7
7955442
J Natl Cancer Inst. 1997 Dec 3;89(23):1813-4
9392625
Cancer Res. 2003 Dec 15;63(24):8912-21
14695208
N Engl J Med. 2001 Mar 15;344(11):783-92
11248153
J Natl Cancer Inst. 2005 Nov 16;97(22):1671-9
16288120
Cancer Immunol Immunother. 2000 Jul;49(4-5):243-52
10941907
Oncology. 1999 Nov;57(4):330-40
10575321
Breast Cancer Res Treat. 1998 Feb;47(3):269-81
9516081
J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89
10995803
Endocr Rev. 1995 Apr;16(2):143-63
7540132
Mol Endocrinol. 1994 Apr;8(4):510-7
8052269
Int J Cancer. 2003 Dec 20;107(6):991-6
14601060
Int J Biochem Cell Biol. 1996 Jun;28(6):619-37
8673727
Br J Cancer. 2003 Jul 7;89(1):81-7
12838305
J Immunol. 1997 Aug 1;159(3):1225-32
9233617